"Naphthyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009287
|
| MeSH Number(s) |
D03.633.100.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naphthyridines".
Below are MeSH descriptors whose meaning is more specific than "Naphthyridines".
This graph shows the total number of publications written about "Naphthyridines" by people in this website by year, and whether "Naphthyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naphthyridines" by people in Profiles.
-
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia. Leukemia. 2021 05; 35(5):1267-1278.
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
-
Neuropharmacology of light-induced locomotor activation. Neuropharmacology. 2015 Aug; 95:243-51.
-
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
-
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb; 100(2):231-7.
-
Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology. 2012 Dec; 63(7):1201-7.
-
Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug; 21(8):1223-33.
-
Orexin-1 receptor mediation of cocaine seeking in male and female rats. J Pharmacol Exp Ther. 2012 Mar; 340(3):801-9.
-
Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci. 2009 Aug; 30(3):493-503.